Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Boris Julg

Showing results (61-70 of 67) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 67 results.
The Lancet. HIV|February 26, 2026
Recommendations from the 2nd Consensus Workshop on Analytical Treatment Interruption in HIV Research TrialsThumbi Ndung'u, Krista L Dong, Donn J Colby, et al.
Nature Medicine|May 13, 2022
Safety and antiviral activity of triple combination broadly neutralizing monoclonal antibody therapy against HIV-1: a phase 1 clinical trialBoris Julg, Kathryn E Stephenson, Kshitij Wagh, et al.
Nature Medicine|October 8, 2021
Safety, pharmacokinetics and antiviral activity of PGT121, a broadly neutralizing monoclonal antibody against HIV-1: a randomized, placebo-controlled, phase 1 clinical trialKathryn E Stephenson, Boris Julg, C Sabrina Tan, et al.
Science Immunology|October 15, 2021
Early cross-coronavirus reactive signatures of humoral immunity against COVID-19Paulina Kaplonek, Chuangqi Wang, Yannic Bartsch, et al.
JAMA|March 11, 2021
Immunogenicity of the Ad26.COV2.S Vaccine for COVID-19Kathryn E Stephenson, Mathieu Le Gars, Jerald Sadoff, et al.
The Lancet. HIV|March 20, 2019
Recommendations for analytical antiretroviral treatment interruptions in HIV research trials-report of a consensus meetingBoris Julg, Lynda Dee, Jintanat Ananworanich, et al.
Annals of Internal Medicine|August 12, 2024
Differentiation of Prior SARS-CoV-2 Infection and Postacute Sequelae by Standard Clinical Laboratory Measurements in the RECOVER CohortKristine M Erlandson, Linda N Geng, Caitlin A Selvaggi, et al.
Pageof 7

Showing results (61-70 of 67) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 67 results.
The Lancet. HIV|February 26, 2026
Recommendations from the 2nd Consensus Workshop on Analytical Treatment Interruption in HIV Research TrialsThumbi Ndung'u, Krista L Dong, Donn J Colby, et al.
Nature Medicine|May 13, 2022
Safety and antiviral activity of triple combination broadly neutralizing monoclonal antibody therapy against HIV-1: a phase 1 clinical trialBoris Julg, Kathryn E Stephenson, Kshitij Wagh, et al.
Nature Medicine|October 8, 2021
Safety, pharmacokinetics and antiviral activity of PGT121, a broadly neutralizing monoclonal antibody against HIV-1: a randomized, placebo-controlled, phase 1 clinical trialKathryn E Stephenson, Boris Julg, C Sabrina Tan, et al.
Science Immunology|October 15, 2021
Early cross-coronavirus reactive signatures of humoral immunity against COVID-19Paulina Kaplonek, Chuangqi Wang, Yannic Bartsch, et al.
JAMA|March 11, 2021
Immunogenicity of the Ad26.COV2.S Vaccine for COVID-19Kathryn E Stephenson, Mathieu Le Gars, Jerald Sadoff, et al.
The Lancet. HIV|March 20, 2019
Recommendations for analytical antiretroviral treatment interruptions in HIV research trials-report of a consensus meetingBoris Julg, Lynda Dee, Jintanat Ananworanich, et al.
Annals of Internal Medicine|August 12, 2024
Differentiation of Prior SARS-CoV-2 Infection and Postacute Sequelae by Standard Clinical Laboratory Measurements in the RECOVER CohortKristine M Erlandson, Linda N Geng, Caitlin A Selvaggi, et al.
Pageof 7